^
    1d
    XTX301-01: XTX301 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=358, Recruiting, Xilio Development, Inc. | Trial completion date: Feb 2027 --> Sep 2028 | Trial primary completion date: Feb 2027 --> Sep 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • EGFR mutation • MSI-H/dMMR • ALK fusion • ROS1 fusion • BRCA mutation • NTRK fusion
    |
    efarindodekin alfa (XTX301)
    6d
    CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=23, Terminated, Cullinan Therapeutics Inc. | N=86 --> 23 | Trial completion date: Jun 2028 --> Jun 2026 | Recruiting --> Terminated | Trial primary completion date: Jun 2028 --> Jun 2026; Company decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab) • CLN-617
    1m
    Immunocytokines based on IL-12 for cancer therapy: Enhancing efficacy and reducing toxicity. (PubMed, Int Rev Cell Mol Biol)
    This has led to clinical trials in which two ICKs, namely huBC1-IL12 and NHS-IL-12 targeting fibronectin extra domain B and DNA/histone complexes, respectively, have been evaluated. These initial trials have shown a high degree of safety, as well as activation of antitumor immune responses in treated patients.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • MSLN (Mesothelin)
    |
    PDS01ADC
    2ms
    A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=68, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    T3011
    2ms
    Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation (clinicaltrials.gov)
    P1, N=20, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Dec 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    2ms
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Imunon | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial primary completion date
    |
    carboplatin • paclitaxel • IMNN-001
    2ms
    ADePT: Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma (clinicaltrials.gov)
    P1/2, N=68, Recruiting, Trogenix ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    valacyclovir
    2ms
    KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma. (PubMed, Mol Ther Oncol)
    Similar findings were observed in metastatic lymph nodes, demonstrating viral activity and tumor suppression. Collectively, these results indicate that KLS-3021 exerts potent anti-tumor efficacy in both primary and metastatic cSCC models, supporting its clinical translation as a multifunctional oncolytic virotherapy targeting the physical and immunological barriers of the tumor microenvironment.
    Journal
    |
    PD-1 (Programmed cell death 1)
    2ms
    PuMP: Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 (clinicaltrials.gov)
    P1, N=51, Recruiting, Duke University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    |
    MVR-C5252
    2ms
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Imunon | Trial completion date: Jan 2028 --> Aug 2028 | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • IMNN-001
    2ms
    A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Virogin Biotech Ltd.
    New P2 trial
    |
    VG201
    3ms
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Shanghai Virogin Biotech Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open